外泌体在前列腺癌诊疗中的研究进展

doi:10.16352/j.issn.1001-6325.2022.01.026

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (1): 163-167.doi: 10.16352/j.issn.1001-6325.2022.01.026

外泌体在前列腺癌诊疗中的研究进展

李英杰, 杨庭楷, 纪志刚^*, 文进^*

中国医学科学院北京协和医学院北京协和医院泌尿外科, 北京 100730

收稿日期:2021-09-07 修回日期:2021-11-05 出版日期:2022-01-05 发布日期:2022-01-05
通讯作者: ^* wjpumch@163.com; jzgjxmc@163.com
基金资助:
中国医学科学院中央级公益性科研院所基本科研业务费临床与转化医学研究基金(2019XK320027); 外国文教专家项目管理基金(G20190001645)

Progress of exosomes in diagnosis and treatment of prostate cancer

LI Ying-jie, YANG Ting-kai, JI Zhi-gang^*, WEN Jin^*

Department of Urology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2021-09-07 Revised:2021-11-05 Online:2022-01-05 Published:2022-01-05
Contact: ^* wjpumch@163.com; jzgjxmc@163.com

摘要/Abstract

摘要： 前列腺癌(PCa)是男性常见的恶性肿瘤。外泌体是存在于人体多种体液中的双层膜囊泡,携带核酸、蛋白等物质,介导细胞间通讯。外泌体可以促进前列腺癌的生长,协助免疫逃逸及化学治疗耐药,诱导血管生成、上皮细胞间充质转化(EMT)并为转移前生态位的形成提供条件,进而促进前列腺癌的侵袭和转移。基于肿瘤细胞与正常细胞分泌的外泌体成分不同,外泌体可作为前列腺癌诊断、预测侵袭转移、评估患者预后及药物疗效的生物标志物,并有望作为药物运输载体,在肿瘤的精准治疗中具有广阔的前景。

关键词: 前列腺癌, 外泌体, 生物标志物, 肿瘤

Abstract: Prostate cancer(PCa) is a common malignancy in males. Exosomes are lipid bilayer vesicles containing protein, mRNA and miRNA, which are active in intercellular communications. Exosomes promotes the development of prostate cancer, support immune evading and chemotherapy resistance, stimulate angiogenesis, induce epithelial-mesenchymal transition(EMT) of tumor cells, and contribute to the formation of pre-metastasis niche, thus promoting the invasion and metastasis of prostate cancer. Based on the role in tumor biological behavior and heterogeneity in different cells, exosomes hold great potentials as biomarker for diagnosis and prognosis of prostate cancer, and are expected to become a favorable drug carrier. It has a promising prospect for cancer therapy.

Key words: prostate cancer, exosomes, biomarkers, tumor

中图分类号:

R737.25

李英杰, 杨庭楷, 纪志刚, 文进. 外泌体在前列腺癌诊疗中的研究进展[J]. 基础医学与临床, 2022, 42(1): 163-167.

LI Ying-jie, YANG Ting-kai, JI Zhi-gang, WEN Jin. Progress of exosomes in diagnosis and treatment of prostate cancer[J]. Basic & Clinical Medicine, 2022, 42(1): 163-167.

参考文献

[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424.
[2]Saini S. PSA and beyond: alternative prostate cancer biomarkers[J]. Cell Oncol (Dordr), 2016, 39: 97-106.
[3]Cocozza F, Grisard E, Martin-Jaular L, et al. Snapshot: extracellular vesicles[J]. Cell, 2020, 182: 262-262.e1. doi: 10.1016/j.cell.2020.04.054.
[4]Albino D, Falcione M, Uboldi V, et al. Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer[J]. Commun Biol, 2021, 4: 119. doi:10.1038/s42003-020-01642-5.
[5]Dai Y, Gao X. Inhibition of cancer cell-derived exosomal microRNA-183 suppresses cell growth and metastasis in prostate cancer by upregulating TPM1[J]. Cancer Cell Int, 2021, 21: 145. doi:10.1186/s12935-020-01686-x.
[6]Herrera M, Llorens C, Rodríguez M, et al. Differential distribution and enrichment of non-coding RNAs in exosomes from normal and cancer-associated fibroblasts in colorectal cancer[J]. Mol Cancer, 2018, 17: 114. doi: 10.1186/s12943-018-0863-4.
[7]Wu M, Wang G, Hu W, et al. Emerging roles and therapeutic value of exosomes in cancer metastasis[J]. Mol Cancer, 2019, 18: 53. doi: 10.1186/s12943-019-0964-8.
[8]Mashouri L, Yousefi H, Aref AR, et al. Exosomes: composition, biogenesis, and mechanisms in cancer meta-stasis and drug resistance[J]. Mol Cancer, 2019, 18: 75. doi: 10.1186/s12943-019-0991-5.
[9]Lorenc T, Klimczyk K, Michalczewska I, et al. Exosomes in prostate cancer diagnosis, prognosis and therapy[J]. Int J Mol Sci, 2020, 21: 2118. doi:10.3390/ijms21062118.
[10]Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560: 382-386.
[11]Sinha D, Roy S, Saha P, et al. Trends in research on exosomes in cancer progression and anticancer therapy[J]. Cancers, 2021, 13: 326. doi:10.3390/cancers13020326.
[12]Li Y, Li Q, Li D, et al. Exosome carrying PSGR promotes stemness and epithelial-mesenchymal transition of low aggressive prostate cancer cells[J]. Life Sci, 2021, 264: 118638. doi:10.1016/j.lfs.2020.118638.
[13]Guo Y, Ji X, Liu J, et al. Effects of exosomes on pre-metastatic niche formation in tumors[J]. Mol Cancer, 2019, 18: 39. doi:10.1186/s12943-019-0995-1.
[14]Akoto T, Saini S. Role of exosomes in prostate cancer metastasis[J]. Int J Mol Sci, 2021, 22: 3528. doi:10.3390/ijms22073528.
[15]Yu L, Sui B, Fan W, et al. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p[J]. J Extracell Vesicles, 2021, 10: e12056. doi:10.1002/jev2.12056.
[16]Borel M, Lollo G, Magne D, et al. Prostate cancer-derived exosomes promote osteoblast differentiation and activity through phospholipase D2[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866: 165919. doi:10.1016/j.bbadis.2020.165919.
[17]Zhang Y, Chen B, Xu N, et al. Exosomes promote the transition of androgen-dependent prostate cancer cells into androgen-independent manner through up-regulating the heme oxygenase-1[J]. Int J Nanomedicine, 2021, 16: 315-327.
[18]Zhang Y, Zhao J, Ding M, et al. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis[J]. J Exp Clin Cancer Res, 2020, 39: 282. doi:10.1186/s13046-020-01761-1.
[19]Shan G, Gu J, Zhou D, et al. Cancer-associated fibroblast-secreted exosomal miR-423-5p promotes chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF-β signaling pathway[J]. Exp Mol Med, 2020, 52: 1809-1822.
[20]Duca RB, Massillo C, Dalton GN, et al. miR-19b-3p and miR-101-3p as potential biomarkers for prostate cancer diagnosis and prognosis[J]. Am J Cancer Res, 2021, 11: 2802-2820.
[21]Ji J, Chen R, Zhao L, et al. Circulating exosomal mRNA profiling identifies novel signatures for the detection of prostate cancer[J]. Mol Cancer, 2021, 20: 58. doi:10.1186/s12943-021-01349-z.
[22]Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer[J]. Eur Urol, 2015, 67: 33-41.
[23]Guo T, Wang Y, Jia J, et al. The identification of plasma exosomal miR-423-3p as a potential predictive biomarker for prostate cancer castration-resistance development by plasma exosomal miRNA sequencing[J]. Front Cell Dev Biol, 2020, 8: 602493. doi:10.3389/fcell.2020.602493.
[24]Shin S, Park YH, Jung SH, et al. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer[J]. NPJ Genom Med, 2021, 6: 45. doi:10.1038/s41525-021-00212-w.
[25]Krishn SR, Singh A, Bowler N, et al. Prostate cancer sheds the αvβ3 integrin in vivo through exosomes[J]. Matrix Biol, 2019, 77: 41-57.
[26]Del Re M, Conteduca V, Crucitta S, et al. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide[J]. Prostate Cancer Prostatic Dis, 2021, 24: 524-531.
[27]Severic M, Ma G, Pereira SGT, et al. Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo[J]. J Control Release, 2021, 330: 101-110.
[28]Gaballa R, Ali HEA, Mahmoud MO, et al. Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate cancer cells by inducing epithelial-mesenchy-mal transition[J]. Cancers (Basel), 2020, 12: 2300. doi:10.3390/cancers12082300.
[29]Han Q, Xie QR, Li F, et al. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer[J]. Theranostics, 2021, 11: 6526-6541.
[30]Xu Z, Zeng S, Gong Z, et al. Exosome-based immunotherapy: a promising approach for cancer treatment[J]. Mol Cancer, 2020, 19: 160. doi:10.1186/s12943-020-01278-3.
[31]Morishita M, Takahashi Y, Matsumoto A, et al. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA[J]. Biomaterials, 2016, 111: 55-65.
[32]Kim J, Shim JS, Han BH, et al. Hydrogel-based hybridization chain reaction (HCR) for detection of urinary exosomal miRNAs as a diagnostic tool of prostate cancer[J]. Biosens Bioelectron, 2021, 192: 113504. doi:10.1016/j.bios.2021.113504.

外泌体在前列腺癌诊疗中的研究进展

Progress of exosomes in diagnosis and treatment of prostate cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	于曼殊, 赵晓敏, 邱明月, 刘春冉, 那日苏. 牙源性干细胞治疗帕金森病的研究进展[J]. 基础医学与临床, 2024, 44(9): 1298-1302.
[2]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[3]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[4]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[5]	赵俊丽, 朱君君, 詹秋楠, 刘苗. 骨髓间充质干细胞来源外泌体抑制高糖诱导的腹膜间皮细胞EMT[J]. 基础医学与临床, 2024, 44(8): 1149-1156.
[6]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[7]	高璐, 蔡孟华, 许依, 何维, 陈慧, 张建民. 过表达膜定位IL-3的293T细胞外泌体的纯化及体外功能验证[J]. 基础医学与临床, 2024, 44(7): 947-953.
[8]	陈笑天, 陈翀, 罗云萍. MAFB对肿瘤相关巨噬细胞极化及功能的影响[J]. 基础医学与临床, 2024, 44(7): 965-973.
[9]	谭树芬, 何利平, 杨琳琳, 杨谢兰, 杨宏英, 姚明姣, 李树清. TBL与工作坊整合教学法在妇科肿瘤学临床教学中的应用[J]. 基础医学与临床, 2024, 44(7): 1054-1057.
[10]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[11]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[12]	王婷婷, 郭丹, 陆君阳, 徐徕, 董海涛, 林佃新, 肖毅. 结直肠神经内分泌肿瘤细胞突变类型分析[J]. 基础医学与临床, 2024, 44(4): 523-527.
[13]	李运龙, 李蕊, 张玉萍, 王瑞, 刘燕萍. 孕期锌缺乏及对妊娠结局的影响[J]. 基础医学与临床, 2024, 44(4): 422-427.
[14]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.
[15]	吴玉红, 喻才元, 叶石才. NMES1基因在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 403-407.